Last reviewed · How we verify

Incyte Corporation — Portfolio Competitive Intelligence Brief

Incyte Corporation (INCY) pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

INCY (NASDAQ) 5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Niktimvo AXATILIMAB marketed Colony Stimulating Factor-1 Receptor Blocker [EPC] Immunology 2024-01-01
Zynyz RETIFANLIMAB marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Programmed cell death protein 1 Oncology 2023-01-01
Pemazyre PEMIGATINIB marketed Kinase Inhibitor [EPC] Fibroblast growth factor receptor 1 Oncology 2020-01-01
ZYNYZ RETIFANLIMAB-DLWR marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Programmed cell death protein 1 Oncology
R-CHOP R-CHOP marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 2 shared drug classes
  2. AbbVie · 1 shared drug class
  3. Bayer · 1 shared drug class
  4. BEIGENE · 1 shared drug class
  5. BRISTOL MYERS SQUIBB · 1 shared drug class
  6. BRISTOL-MYERS SQUIBB · 1 shared drug class
  7. AstraZeneca · 1 shared drug class
  8. ASTRAZENECA LP · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Incyte Corporation:

Cite this brief

Drug Landscape (2026). Incyte Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/incyte. Accessed 2026-05-13.

Related